Cargando…
Safety and pharmacokinetics of the orally available antiprionic compound PRI‐002: A single and multiple ascending dose phase I study
INTRODUCTION: PRI‐002 is an orally available anti–amyloid beta (Aβ) prionic compound developed for direct disassembly of toxic Aβ oligomers relevant to Alzheimer's disease. METHODS: Two placebo‐controlled clinical phase I trials with oral dosing of PRI‐002 were conducted in healthy young subjec...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087413/ https://www.ncbi.nlm.nih.gov/pubmed/32211506 http://dx.doi.org/10.1002/trc2.12001 |